Getting your Trinity Audio player ready...
The article in the Oct. 31 Parade magazine describes the importance of Chronic Fatigue Syndrome (CFS) but fails to give up-to-date information concerning its treatment.
Intravenous gamma globulin, which is mentioned in the article, has been studied in prospective clinical trials and has been found to be ineffective.
On the other hand, recent clinical studies demonstrating the benefit of fluorocortisone in CFS patients with orthostatic intolerance (decreased blood pressure while standing) were not mentioned in the article. Between 40 percent and 75 percent of adults with CFS have orthostatic intolerance and are likely to benefit from measures correcting orthostatic intolerance that include the use of fluorocortisone.
